CRSP
Price
$46.70
Change
-$0.08 (-0.17%)
Updated
Jun 26 closing price
Capitalization
4.03B
45 days until earnings call
PGEN
Price
$1.43
Change
-$0.07 (-4.67%)
Updated
Jun 26 closing price
Capitalization
422.11M
45 days until earnings call
Interact to see
Advertisement

CRSP vs PGEN

Header iconCRSP vs PGEN Comparison
Open Charts CRSP vs PGENBanner chart's image
CRISPR Therapeutics AG
Price$46.70
Change-$0.08 (-0.17%)
Volume$2.68M
Capitalization4.03B
Precigen
Price$1.43
Change-$0.07 (-4.67%)
Volume$1.45M
Capitalization422.11M
CRSP vs PGEN Comparison Chart in %
Loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRSP vs. PGEN commentary
Jun 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a StrongBuy and PGEN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 27, 2025
Stock price -- (CRSP: $46.70 vs. PGEN: $1.43)
Brand notoriety: CRSP and PGEN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 121% vs. PGEN: 92%
Market capitalization -- CRSP: $4.03B vs. PGEN: $422.11M
CRSP [@Biotechnology] is valued at $4.03B. PGEN’s [@Biotechnology] market capitalization is $422.11M. The market cap for tickers in the [@Biotechnology] industry ranges from $301.01B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whilePGEN’s FA Score has 0 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • PGEN’s FA Score: 0 green, 5 red.
According to our system of comparison, both CRSP and PGEN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 6 TA indicator(s) are bullish while PGEN’s TA Score has 3 bullish TA indicator(s).

  • CRSP’s TA Score: 6 bullish, 4 bearish.
  • PGEN’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, CRSP is a better buy in the short-term than PGEN.

Price Growth

CRSP (@Biotechnology) experienced а +5.11% price change this week, while PGEN (@Biotechnology) price change was -4.03% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.59%. For the same industry, the average monthly price growth was +34.25%, and the average quarterly price growth was +14.95%.

Reported Earning Dates

CRSP is expected to report earnings on Aug 11, 2025.

PGEN is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+3.59% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($4.03B) has a higher market cap than PGEN($422M). PGEN YTD gains are higher at: 27.679 vs. CRSP (18.648). PGEN has higher annual earnings (EBITDA): -154.85M vs. CRSP (-455.24M). CRSP has more cash in the bank: 1.86B vs. PGEN (80.2M). PGEN has less debt than CRSP: PGEN (5.42M) vs CRSP (219M). CRSP has higher revenues than PGEN: CRSP (35M) vs PGEN (4.2M).
CRSPPGENCRSP / PGEN
Capitalization4.03B422M956%
EBITDA-455.24M-154.85M294%
Gain YTD18.64827.67967%
P/E RatioN/AN/A-
Revenue35M4.2M833%
Total Cash1.86B80.2M2,313%
Total Debt219M5.42M4,043%
FUNDAMENTALS RATINGS
CRSP vs PGEN: Fundamental Ratings
CRSP
PGEN
OUTLOOK RATING
1..100
2221
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
70
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
94100
PRICE GROWTH RATING
1..100
4043
P/E GROWTH RATING
1..100
79100
SEASONALITY SCORE
1..100
4630

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRSP's Valuation (67) in the Biotechnology industry is in the same range as PGEN (70) in the null industry. This means that CRSP’s stock grew similarly to PGEN’s over the last 12 months.

CRSP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PGEN (100) in the null industry. This means that CRSP’s stock grew similarly to PGEN’s over the last 12 months.

CRSP's SMR Rating (94) in the Biotechnology industry is in the same range as PGEN (100) in the null industry. This means that CRSP’s stock grew similarly to PGEN’s over the last 12 months.

CRSP's Price Growth Rating (40) in the Biotechnology industry is in the same range as PGEN (43) in the null industry. This means that CRSP’s stock grew similarly to PGEN’s over the last 12 months.

CRSP's P/E Growth Rating (79) in the Biotechnology industry is in the same range as PGEN (100) in the null industry. This means that CRSP’s stock grew similarly to PGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPPGEN
RSI
ODDS (%)
Bearish Trend 1 day ago
88%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
83%
MACD
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 15 days ago
84%
N/A
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
86%
Aroon
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OILVX19.530.16
+0.83%
Optimum Large Cap Value Instl
CMCIX26.00N/A
N/A
Calvert Small/Mid-Cap I
NOSGX12.57N/A
N/A
Northern Small Cap Value
CIRRX17.67N/A
N/A
Cohen & Steers Real Estate Securities R
NEMIX22.88N/A
N/A
Neuberger Berman Emerg Mkts Eq I

PGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, PGEN has been loosely correlated with ARCT. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if PGEN jumps, then ARCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PGEN
1D Price
Change %
PGEN100%
-4.67%
ARCT - PGEN
47%
Loosely correlated
+3.30%
CRSP - PGEN
45%
Loosely correlated
-0.17%
XENE - PGEN
44%
Loosely correlated
+1.39%
ALEC - PGEN
44%
Loosely correlated
+0.67%
PRME - PGEN
44%
Loosely correlated
+9.50%
More